==NILAI PRETEST Pre-postest Endokrin 2

370Mechanisms of Hormone Action J. Larry Jameson Hormones function as a communication system within the body. The endocrine system, composed of various glands and the hormones they produce, interacts with essentially all other physiologic systems to regulate growth, metabolism, homeostasis, and reproduction. Because hormones circulate and act via receptors in target tissues, they serve to integrate physiologic responses to external or internal cues. For exam ple, the light-dark cycle, sensed through the visual system, modulates hypothalamic corticotopin-releasing hormone (CRH), which increases pituitary adrenocorticotropin hormone (ACTH) production, leading to increased adrenal cortisol production before the time of waking in the morning. Increased cortisol, in turn, circulates throughout the body, acting via the nuclear glucocorticoid receptor, to activate numer ous genetic programs that influence metabolism, the cardiovascular system, behavior, and the immune system. This chapter provides an overview of the different types of hormones and how they function at the cellular level to control myriad physiologic processes. CLASSES OF HORMONES Hormones can be divided into five major types: (1) amino acid deriv atives such as dopamine, catecholamine, and thyroid hormone; (2) small neuropeptides such as gonadotropin-releasing hormone (GnRH), thyrotropin-releasing hormone (TRH), somatostatin, and vasopressin; (3) large proteins such as insulin, luteinizing hormone (LH), and parathy roid hormone (PTH); (4) steroid hormones such as cortisol and estrogen that are synthesized from cholesterol-based precursors; and (5) vitamin derivatives such as retinoids (vitamin A) and vitamin D. A variety of peptide growth factors, most of which act locally, share actions with hor mones. As a rule, amino acid derivatives and peptide hormones inter act with cell-surface membrane receptors. Steroids, thyroid hormones, vitamin D, and retinoids are lipid-soluble and interact with intracel lular nuclear receptors, although many also interact with membrane receptors or intracellular signaling proteins as well. ■HORMONE AND RECEPTOR FAMILIES Hormones and receptors can be grouped into families, reflecting struc tural similarities and evolutionary origins (Table 370-1). The evolution of these families generates diverse but highly selective pathways of hormone action. Recognition of these relationships has proven useful for extrapolating information gleaned from one hormone or receptor to other family members. The glycoprotein hormone family, consisting of thyroid-stimulating hormone (TSH), follicle-stimulating hormone (FSH), LH, and human chorionic gonadotropin (hCG), illustrates many features of evolution arily related hormones. The glycoprotein hormones are heterodimers that share the α subunit in common; the β subunits are distinct and confer specific biologic actions. The overall three-dimensional archi tecture of the β subunits is similar, reflecting the locations of conserved disulfide bonds that restrain protein conformation. The cloning of the β-subunit genes from multiple species suggests that this family arose from a common ancestral gene, probably by gene duplication and sub sequent divergence to evolve new biologic functions. As hormone families enlarge and diverge, their receptors must co-evolve to derive new biologic functions. Related G protein–coupled receptors (GPCRs), for example, have evolved for each of the glycopro tein hormones. These receptors are also structurally similar, and each is coupled predominantly to the Gs α signaling pathway. However, there is minimal overlap of hormone binding. For example, TSH binds with high specificity to the TSH receptor but interacts minimally with the LH or FSH receptors. Nonetheless, there can be subtle physiologic consequences of hormone cross-reactivity with other receptors. Very high levels of hCG during pregnancy stimulate the TSH receptor and TABLE 370-1 Examples of Membrane Receptor Families and Signaling Pathways RECEPTORS EFFECTORS SIGNALING PATHWAYS G Protein–Coupled Seven-Transmembrane Receptor (GPCR) β-Adrenergic, LH, FSH, TSH Glucagon, PTH, PTHrP, ACTH, MSH, GHRH, CRH α-Adrenergic, somatostatin TRH, GnRH Gs α, adenylate cyclase Ca2+ channels Gi α Gq , G11 Stimulation of cyclic AMP production, protein kinase A Calmodulin, Ca2+-dependent kinases Inhibition of cyclic AMP production Activation of K+, Ca2+ channels Phospholipase C, diacyl-glycerol, IP3 , protein kinase C, voltage-dependent Ca2+ channels Receptor Tyrosine Kinase Insulin, IGF-I EGF, NGF Tyrosine kinases, IRS Tyrosine kinases, ras MAP kinases, PI 3-kinase; AKT Raf, MAP kinases, RSK Cytokine Receptor–Linked Kinase GH, PRL JAK, tyrosine kinases STAT, MAP kinase, PI 3-kinase, IRS-1 Serine Kinase Activin, TGF-β, MIS Serine kinase Smads Abbreviations: IP3 , inositol triphosphate; IRS, insulin receptor substrates; MAP, mitogen-activated protein; MSH, melanocyte-stimulating hormone; NGF, nerve growth factor; PI, phosphatidylinositol; RSK, ribosomal S6 kinase; TGF-β, transforming growth factor β. For all other abbreviations, see text. Note that most receptors interact with multiple effectors and activate networks of signaling pathways.increase thyroid hormone levels, resulting via feedback inhibition in a compensatory decrease in TSH. Insulin and insulin-like growth factor I (IGF-I) and IGF-II have struc tural similarities that are most apparent when precursor forms of the proteins are compared. In contrast to the high degree of specificity seen with the glycoprotein hormones, there is moderate cross-talk among the members of the insulin/IGF family. High concentrations of an IGF-II precursor produced by certain tumors (e.g., sarcomas) can cause hypoglycemia, partly because of binding to insulin and IGF-I receptors (Chap. 403). High concentrations of insulin also bind to the IGF-I recep tor, perhaps accounting for some of the clinical manifestations seen in conditions with chronic hyperinsulinemia. Another important example of receptor cross-talk is seen with PTH and parathyroid hormone–related peptide (PTHrP) (Chap. 403). PTH is produced by the parathyroid glands, whereas PTHrP is expressed at high levels during development and by a variety of tumors (Chap. 89). These hormones have amino acid sequence similarity, particularly in their amino-terminal regions. Both hormones bind to the PTH1R recep tor that is expressed in bone and kidney. Hypercalcemia and hypoph osphatemia therefore may result from excessive production of either hormone, making it difficult to distinguish hyperparathyroidism from hypercalcemia of malignancy solely on the basis of serum chemistries. However, sensitive and specific assays for PTH and PTHrP now allow these disorders to be distinguished more readily. Based on their specificities for DNA-binding sites, the nuclear receptor family can be subdivided into type 1 receptors (glucocorticoid receptor, mineralocorticoid receptor, androgen receptor, estrogen receptor, proges terone receptor) that bind steroids and type 2 receptors (thyroid hormone receptor, vitamin D receptor, retinoic acid receptor, peroxisome prolifer ator activated receptor) that bind thyroid hormone, vitamin D, retinoic acid, or lipid derivatives, respectively. Certain functional domains in nuclear receptors, such as the zinc finger DNA-binding domains, are highly conserved. However, selective amino acid differences within this domain confer DNA sequence specificity. The hormone-binding domains are more variable, providing great diversity in the array of small molecules that bind to different nuclear receptors. With fewexceptions, hormone binding is highly specific for a single type of nuclear receptor. One exception involves the glucocorticoid and mineralocorticoid receptors. Because the mineralocorticoid receptor also binds glucocorticoids with high affinity, an enzyme (11β-hydrox ysteroid dehydrogenase) in renal tubular cells inactivates glucocor ticoids, allowing selective responses to mineralocorticoids such as aldosterone. However, when very high glucocorticoid concentrations occur, as in Cushing’s syndrome, the glucocorticoid degradation pathway becomes saturated, allowing excessive cortisol levels to bind mineralocorticoid receptors leading to sodium retention and potas sium wasting. This phenomenon is particularly pronounced in ectopic adrenocorticotropic hormone (ACTH) syndromes (Chap. 379). Another example of relaxed nuclear receptor specificity involves the estrogen receptor, which can bind an array of compounds, some of which have little apparent structural similarity to the high-affinity ligand estradiol. This feature of the estrogen receptor makes it susceptible to activation by “environmental estrogens” such as resveratrol, octylphenol, and many other aromatic hydrocarbons. However, this lack of specificity provides an opportunity to synthesize a remarkable series of clinically useful antagonists (e.g., tamoxifen) and selective estrogen response modulators (SERMs) such as raloxifene. These compounds generate distinct conformations that alter receptor interactions with components of the transcription machinery (see below), thereby conferring their unique actions. ■HORMONE SYNTHESIS AND PROCESSING The synthesis of peptide hormones and their receptors occurs through a classic pathway of gene expression: transcription → mRNA → protein → posttranslational protein processing → intracellular sorting, followed by membrane integration or secretion. Many hormones are embedded within larger precursor polypep tides that are proteolytically processed to yield the biologically active hormone. Examples include proopiomelanocortin (POMC) → ACTH; proglucagon → glucagon; proinsulin → insulin; and pro-PTH → PTH, among others. In many cases, such as POMC and proglucagon, these precursors generate multiple biologically active peptides. It is pro vocative that hormone precursors are typically inactive, presumably adding an additional level of regulatory control. Prohormone conver sion occurs not only for peptide hormones but also for certain steroids (testosterone → dihydrotestosterone) and thyroid hormone (T4 → T3 ). Peptide precursor processing is intimately linked to intracellular sorting pathways that transport proteins to appropriate vesicles and enzymes, resulting in specific cleavage steps, followed by protein folding and translocation to secretory vesicles. Hormones destined for secretion are translocated across the endoplasmic reticulum under the guidance of an amino-terminal signal sequence that subsequently is cleaved. Cell-surface receptors are inserted into the membrane via short segments of hydrophobic amino acids that remain embedded within the lipid bilayer. During translocation through the Golgi and endoplasmic reticulum, hormones and receptors are subject to a variety of posttranslational modifications, such as glycosylation and phospho rylation, which can alter protein conformation, modify circulating half life, and alter biologic activity. Synthesis of most steroid hormones is based on modifications of the precursor, cholesterol. Multiple regulated enzymatic steps are required for the synthesis of testosterone (Chap. 384), estradiol (Chap. 385), cortisol (Chap. 379), and vitamin D (Chap. 402). This large number of synthetic steps predisposes to multiple genetic and acquired disorders of steroidogenesis. Endocrine genes contain regulatory DNA elements similar to those found in many other genes, but their exquisite control by hormones reflects the presence of specific hormone response elements. For exam ple, the TSH genes are repressed directly by thyroid hormones acting through the thyroid hormone receptor (TR), a member of the nuclear receptor family. Steroidogenic enzyme gene expression requires spe cific transcription factors, such as steroidogenic factor-1 (SF-1), acting in conjunction with signals transmitted by trophic hormones (e.g., ACTH or LH). Once activated, SF-1 functions as a master regulator, inducing a large array of genes required for steroidogenic and metabolic pathways The circulating level of a hormone is determined by its rate of secre tion and its half-life. After protein processing, peptide hormones (e.g., GnRH, insulin, growth hormone [GH]) are stored in secretory granules. As these granules mature, they are poised beneath the plasma mem brane for imminent release into the circulation. In most instances, the stimulus for hormone secretion is a releasing factor or neural signal that induces rapid changes in intracellular calcium concentrations, leading to secretory granule fusion with the plasma membrane and release of its contents into the extracellular environment and blood stream. Steroid hormones, in contrast, diffuse into the circulation as they are synthesized. Thus, their secretory rates are closely aligned with rates of synthesis. For example, ACTH and LH induce steroido genesis by stimulating the activity of the steroidogenic acute regulatory (StAR) protein (transports cholesterol into the mitochondrion) along with other rate-limiting steps (e.g., cholesterol side-chain cleavage enzyme, CYP11A1) in the steroidogenic pathway. Hormone transport and degradation dictate the rapidity with which a hormonal signal decays. Some hormone signals are evanescent (e.g., somatostatin), whereas others are longer-lived (e.g., TSH). Because somatostatin exerts effects in virtually every tissue, a short half-life allows its concentrations and actions to be controlled locally. Structural modifications that impair somatostatin degradation have been useful for generating long-acting therapeutic analogues such as octreotide (Chap. 373). In contrast, the actions of TSH are highly specific for the thyroid gland. Its prolonged half-life accounts for relatively constant serum levels even though TSH is secreted in discrete pulses. An understanding of circulating hormone half-life is important for achieving physiologic hormone replacement, as the frequency of dosing and the time required to reach steady state are intimately linked to rates of hormone decay. T4 , for example, has a circulating half-life of 7 days. Consequently, >1 month is required to reach a new steady state, and single daily doses are sufficient to achieve constant hormone levels. T3 , in contrast, has a half-life of 1 day. Its administration is associated with more dynamic serum levels, and it must be administered two to three times per day. Similarly, synthetic glucocorticoids vary widely in their half-lives; those with longer half-lives (e.g., dexamethasone) are asso ciated with greater suppression of the hypothalamic-pituitary-adrenal (HPA) axis. Most protein hormones (e.g., ACTH, GH, prolactin [PRL], PTH, LH) have relatively short half-lives (<20 min), leading to sharp peaks of secretion and decay. The only accurate way to profile the pulse frequency and amplitude of these hormones is to measure levels in frequently sampled blood (every 10 min or less) over long durations (8–24 h). Because this is not practical in a clinical setting, an alternative strategy is to pool three to four samples drawn at about 30-min inter vals, or interpret the results in the context of a relatively wide normal range. Rapid hormone decay is useful in certain clinical settings. For example, the short half-life of PTH allows the use of intraoperative PTH determinations to confirm successful removal of a parathyroid adenoma. This is particularly valuable diagnostically when there is a possibility of multicentric disease or parathyroid hyperplasia, as occurs with multiple endocrine neoplasia (MEN) or renal insufficiency. Many hormones circulate in association with serum-binding pro teins. Examples include (1) T4 and T3 binding to thyroxine-binding globulin (TBG), albumin, and thyroxine-binding prealbumin (TBPA); (2) cortisol binding to cortisol-binding globulin (CBG); (3) androgen and estrogen binding to sex hormone–binding globulin (SHBG); (4) IGF-I and II binding to multiple IGF-binding proteins (IGFBPs); (5) GH interactions with GH-binding protein (GHBP), a circulating fragment of the GH receptor extracellular domain; and (6) activin binding to follistatin. These interactions provide a hormonal reser voir, prevent otherwise rapid degradation of unbound hormones,restrict hormone access to certain sites (e.g., IGFBPs), and modulate the unbound, or “free,” hormone concentrations. Although a variety of binding protein abnormalities have been identified, most have little clinical consequence aside from creating diagnostic problems. For example, TBG deficiency can reduce total thyroid hormone levels greatly but the free concentrations of T4 and T3 remain normal. Liver disease and certain medications can also influence binding protein levels (e.g., estrogen increases TBG) or cause displacement of hor mones from binding proteins (e.g., salsalate displaces T4 from TBG). In general, only unbound hormone is available to interact with receptors and thus elicit a biologic response. Short-term perturbations in binding proteins change the free hormone concentration, which in turn induces compensatory adaptations through feedback loops. SHBG changes in women are an exception to this self-correcting mechanism. When SHBG decreases because of insulin resistance or androgen excess, the unbound testosterone concentration is increased, potentially contrib uting to hirsutism in women with polycystic ovary syndrome (PCOS) (Chap. 387). The increased unbound testosterone level does not result in an adequate compensatory feedback correction because estrogen, not testosterone, is the primary regulator of the reproductive axis. An additional exception to the unbound hormone hypothesis involves megalin, a member of the low-density lipoprotein (LDL) receptor family that serves as an endocytotic receptor for thyroglobu lin, carrier-bound vitamins A and D and SHBG-bound androgens and estrogens. After internalization, the carrier proteins are degraded in lysosomes and release their bound ligands within the cells. Membrane transporters have also been identified for thyroid hormones. Hormone degradation can be an important mechanism for regulat ing concentrations locally. As noted above, 11β-hydroxysteroid dehy drogenase inactivates glucocorticoids in renal tubular cells, preventing actions through the mineralocorticoid receptor. Thyroid hormone deiodinases convert T4 to T3 and can inactivate T3. During development, degradation of retinoic acid by Cyp26b1 prevents primordial germ cells in the male from entering meiosis, as occurs in the female ovary. ■HORMONE ACTION THROUGH RECEPTORS Receptors for hormones are divided into two major classes: membrane and nuclear. Membrane receptors primarily bind peptide hormones and catecholamines. Nuclear receptors bind small molecules that can diffuse across the cell membrane, such as steroids and vitamin D. Certain general principles apply to hormone-receptor interactions regardless of the class of receptor. Hormones bind to receptors with specificity and an affinity that generally coincides with the dynamic range of circulating hormone concentrations. Low concentrations of free hor mone (usually 10–12 to 10–9 M) rapidly associate and dissociate from receptors in a bimolecular reaction such that the occupancy of the receptor at any given moment is a function of hormone concentration and the recep tor’s affinity for the hormone. Receptor numbers vary greatly in different target tissues, providing one of the major determinants of specific tissue responses to circulating hormones. For example, ACTH receptors are located almost exclusively in the adrenal cortex, and FSH receptors are found predominantly in the gonads. In contrast, insulin and TRs are widely distributed, reflecting the need for metabolic responses in all tissues. size and are the major binding site for large hormones. The trans membrane-spanning regions are composed of hydrophobic α-helical domains that traverse the lipid bilayer. Like some channels, these domains are thought to circularize and form a hydrophobic pocket into which certain small ligands fit. Hormone binding induces conforma tional changes in these domains, transducing structural changes to the intracellular domain, which is a docking site for G proteins. The large family of G proteins, so named because they bind guanine nucleotides (guanosine triphosphate [GTP], guanosine diphosphate [GDP]), provides great diversity for coupling receptors to different signaling pathways. G proteins form a heterotrimeric complex that is composed of various α and βγ subunits (Fig. 370-2). The α subunit contains the guanine nucleotide–binding site and an intrinsic GTPase that hydrolyzes GTP → GDP. The βγ subunits are tightly associated and modulate the activity of the α subunit as well as mediating their own effector signaling pathways. G protein activity is regulated by a cycle that involves GTP hydrolysis and dynamic interactions between the α and βγ subunits. Hormone binding to the receptor induces GDP disso ciation, allowing Gα to bind GTP and dissociate from the βγ complex. Under these conditions, the Gα subunit is activated and mediates sig nal transduction through various enzymes, such as adenylate cyclase and phospholipase C. GTP hydrolysis to GDP allows reassociation with the βγ subunits and restores the inactive state. G proteins interact with other cellular proteins, including kinases, channels, G protein–coupled receptor kinases (GRKs), and arrestins, that mediate signaling as well as receptor desensitization and recycling. A variety of endocrinopathies result from mutations in GPCR recep tors that alter their interactions with G proteins (Table 370-2). Loss-of function mutations are generally recessive and inactivate the relevant hormone signaling pathway. Because many of these receptors are important for development as well as signaling, patient presentations often resemble glandular failure syndromes (e.g., mutations in LH-R, FSH-R, TSH-R). Gain-of-function mutations involve a more complex mechanism. Selected mutations induce conformational changes in the GPCR that mimic the activated state normally induced by hormone binding. These mutations result in a constitutively active state in which G protein coupling stimulates cell signaling pathways, most commonly via cyclic adenosine 5′-monophosphate (cAMP) and protein kinase A. When mutations occur in the germline, the conditions are heritable and present in early life (e.g., LH-R, TSH-R). Somatic mutations can also occur and result in clonal expansion of hyperfunctioning cells. Mutations in the TSH-R illustrate the range of possible clinical con sequences of GPCR mutations. Recessive inactivating mutations in the TSH-R cause congenital hypothyroidism with thyroid gland hypopla sia and resistance to TSH. Clinically, the hormone profile resembles CHAPTER 370 Mechanisms of Hormone Action Cytokine/GH/PRL Activin/MIS/BMP TGF-β Serine kinase ■MEMBRANE RECEPTORS Membrane receptors for hormones can be divided into several major groups: (1) seven transmem brane GPCRs, (2) tyrosine kinase receptors, (3) cytokine receptors, and (4) serine kinase receptors (Fig. 370-1). The seven transmembrane GPCR family binds a remarkable array of hormones, including large proteins (e.g., LH, PTH), small peptides (e.g., TRH, somatostatin), catecholamines (epinephrine, dopamine), and even minerals (e.g., calcium). The extracellular domains of GPCRs vary widely in G protein–coupled Seven transmembrane Insulin/IGF-I Tyrosine kinase JAK/STAT Smads G protein PKA, PKC Target gene Ras/Raf MAPK Nucleus Growth factor Tyrosine kinase Membrane FIGURE 370-1 Membrane receptor signaling. MAPK, mitogen-activated protein kinase; PKA, C, protein kinase A, C; TGF, transforming growth factor. For other abbreviations, see text. 2656 G protein-coupled receptor Membrane PART 12 β γ Gαs GTP cAMP Cell growth and signaling Endocrinology and Metabolism Ligand bound GTP GDP Cycling Gαs GDP β γ Ligand unbound FIGURE 370-2 G protein signaling. G protein-coupled receptors signal via the family of G proteins, so-named because they bind guanylyl nucleotides. In the example shown, a G-protein-coupled receptor (GPCR) bound to a ligand induces GDP dissociation, allowing Gsα to bind GTP and dissociate from the βγ complex. GTP bound Gsα increases cAMP production by adenylyl cyclase and activates the protein kinase A pathway. Not shown are separate signaling pathways activated by the βγ complex. When GTP is converted to GDP by an intrinsic GTPase, the βγ subunits reassociate with GDP-bound Gsα and the complex returns to an inactive state. As noted in the text, mutations in Gsα that eliminate GTPase activity result in constitutive activation of receptor signaling pathways because GTP-bound Gsα cannot be converted to its GDP-bound inactive state. cAMP, cyclic adenosine 5′-monophosphate; GDP, guanosine diphosphate; Gsα, G protein α; GTP, guanosine triphosphate. primary hypothyroidism with low T4 and high TSH. On the other hand, germline activating mutations cause congenital hyperthyroid ism. The disorder is autosomal dominant because an activating muta tion of one TSH-R allele is sufficient to induce cellular hyperfunction and disease. Because the TSH-R is activated in every cell of the thyroid, TABLE 370-2 Genetic Causes of G protein Receptor Disorders RECEPTOR LH FSH TSH GnRH Kisspeptin TRH GHRH PTH Calcium sensing receptor Arginine vasopressin receptor 2 ACTH DISORDER Leydig cell hypoplasia (male) Primary amenorrhea, resistance to LH (female) Familial male precocious puberty (male) Leydig cell adenoma, precocious puberty (male) Hypergonadotropic ovarian failure (female) Hypospermia (male) Ovarian hyperstimulation (female) Congenital hypothyroidism, TSH resistance Nonautoimmune familial hyperthyroidism Hyperfunctioning thyroid adenoma Hypogonadotropic hypogonadism Hypogonadotropic hypogonadism Precocious puberty Central hypothyroidism GH deficiency GENETICS AR, inactivating AR, inactivating AD, activating Sporadic, activating AR, inactivating AR, inactivating AD, activating AR, AD, inactivating AD, activating Sporadic, activating AR, inactivating AR, inactivating AD, activating AR, inactivating AR, inactivating Blomstrand chondrodysplasia Jansen metaphyseal chondrodysplasia Familial hypocalciuric hypercalcemia Neonatal severe hyperparathyroidism Familial hypocalcemic hypercalciura Nephrogenic diabetes insipidus Nephrogenic SIADH Familial ACTH resistance Melanocortin 4 Severe obesity AR, inactivating AD, activating AD, inactivating AR, inactivating AD, activating XL, inactivating XL, activating AR, inactivating there is hyperplastic growth and hyperfunction that resembles the pathology seen in Graves’ disease. This unusual disorder presents in infancy and must be distinguished from the more common clinical circumstance in which maternal antibodies in women with active or previously treated Graves’ disease cross the placenta and stimulate the thyroid gland of the fetus. If an activating TSH-R mutation occurs later in life, in the somatic tissue, there is clonal expansion of the thyrocyte harboring the mutation, ultimately leading to an autonomous hyperfunctioning thyroid nodule. Of note, a similar condition can be caused by somatic mutations in Gsα. In this case, the Gsα GTPase is inactivated and GTP cannot be converted to GDP. Consequently, the Gsα signaling pathway in this particular cell is constitutively active, mimicking chronic TSH stimulation and again leading to clonal expansion and an autono mous hyperfunctioning thyroid nodule. About one-third of hyperfunctioning “hot” thyroid nodules harbor mutations in either the TSH-R or Gsα (TSH-R mutations are more common). Gsα mutations in tissues other than the thyroid can also cause endocrine disease. For example, Gsα mutations in pituitary soma totropes mimic activation of the growth hor mone–releasing hormone (GHRH) pathway and lead to GH-producing adenomas and acro megaly. Rarely, mutations in other components of the protein kinase A pathway in somatotropes can also cause GH-producing adenomas. Gsα mutations that occur early in development (typically mosaic) cause McCune-Albright syndrome (Chap. 405) and the clinical features are manifest because the activated G protein pathway mimics the actions of various hormones (PTH, melanocyte stimulating hormone [MSH], TSH, GHRH) in different tissues. Germline inactivating Gsα mutations cause a range of disorders that are transmitted and expressed in a complex man ner because the locus is imprinted (Chap. 403). These conditions include Albright’s hereditary osteodystrophy (AHO), pseudopseudohypo parathyroidism (PPHP), and pseudohypo parathyroidism types 1b, 1c, and 2. The tyrosine kinase receptors transduce sig nals for insulin and a variety of growth factors, such as IGF-I, epidermal growth factor (EGF), nerve growth factor, platelet-derived growth factor, and fibroblast growth factor. The cysteine-rich extracellular domains contain binding sites for the growth factors. After lig and binding, this class of receptors undergoes autophosphorylation, inducing interactions with intracellular adaptor proteins such as Shc and insulin receptor substrates (IRS). In the case of the insulin receptor, multiple kinases are activated, including the Raf-Ras-MAPK and the Akt/protein kinase B pathways. The tyrosine kinase receptors play a prominent role in cell growth and differentiation as well as in intermediary metabolism. The GH and PRL receptors belong to the cytokine receptor family. Analogous to the tyrosine kinase receptors, ligand binding induces receptor interaction with intracellu lar kinases—the Janus kinases (JAKs), which phosphorylate members of the signal trans duction and activators of transcription (STAT) Codominant, inactivating Abbreviations: ACTH, adrenocorticotropin hormone; AD, autosomal dominant; AR, autosomal recessive; FSH, follicle-stimulating hormone; GH, growth hormone; GHRH, growth hormone–releasing hormone; GnRH, gonadotropin-releasing hormone; LH, luteinizing hormone; PTH, parathyroid hormone; SIADH, syndrome of inappropriate antidiuretic hormone secretion; TRH, thyrotropin-releasing hormone; TSH, thyroid-stimulating hormone; XL, X-linked. 2657 family—as well as with other signaling pathways (Ras, PI3-K, MAPK). The activated STAT proteins translocate to the nucleus and stimulate expression of target genes. The serine kinase receptors mediate the actions of activins, transform ing growth factor β, müllerian-inhibiting substance (MIS, also known as anti-müllerian hormone, AMH), and bone morphogenic proteins (BMPs). This family of receptors (consisting of type I and II subunits) signals through proteins termed smads (fusion of terms for Caenorhab ditis elegans sma + mammalian mad). Like the STAT proteins, the smads serve a dual role of transducing the receptor signal and acting as transcription factors. The pleomorphic actions of these growth fac tors dictate that they act primarily in a local (paracrine or autocrine) manner. Binding proteins such as follistatin (which binds activin and other members of this family) function to inactivate the growth factors and restrict their distribution. Disease-causing mutations also occur in each of these classes of receptors. For example, insulin receptor mutations cause an extreme form of insulin resistance. GH receptor mutations cause Laron-type dwarfism, characterized by low IGF-1 and high GH. AMH receptor mutations cause persistent Müllerian duct syndrome. These hormone resistance syndromes are autosomal recessive and relatively uncom mon. Unlike the GPCRs, activating mutations are unusual, although they do occur for the RET tyrosine kinase receptor, which causes the autosomal dominant disorder multiple endocrine neoplasia type 2 (MEN-2) (Chap. 381). ■NUCLEAR RECEPTORS The family of nuclear receptors has grown to nearly 100 members, many of which are still classified as orphan receptors because their ligands, if they exist, have not been identified (Fig. 370-3). Otherwise, most nuclear receptors are classified on the basis of their ligands. Although all nuclear receptors ultimately act to increase or decrease gene transcription, some (e.g., glucocorticoid receptor) reside primarily in the cytoplasm, whereas others (e.g., TR) are located in the nucleus. After ligand binding, the cytoplasmically localized receptors translo cate to the nucleus. There is growing evidence that certain nuclear receptors (e.g., glucocorticoid, estrogen) can also act at the membrane or in the cytoplasm to activate or repress signal transduction pathways, providing a mechanism for cross-talk between membrane and nuclear receptors. The structures of nuclear receptors have been studied exten sively, including by x-ray crystallography. The DNA-binding domain, Homodimer Steroid Receptors ER, AR, PR, GR Heterodimer Receptors TR, VDR, RAR, PPAR consisting of two zinc fingers, contacts-specific DNA recognition sequences in target genes. Most nuclear receptors bind to DNA as dimers. Consequently, each monomer recognizes an individual DNA motif, referred to as a “half-site.” The steroid receptors, including the glucocorticoid, estrogen, progesterone, and androgen receptors, bind to DNA as homodimers. Consistent with this twofold symmetry, their DNA recognition half-sites are palindromic. The thyroid, retinoid, per oxisome proliferator activated, and vitamin D receptors bind to DNA preferentially as heterodimers in combination with retinoid X receptors (RXRs). Their DNA half-sites are typically arranged as direct repeats. The carboxy-terminal hormone-binding domain mediates transcrip tional control. For type II receptors such as TR and retinoic acid recep tor (RAR), co-repressor proteins bind to the receptor in the absence of ligand and silence gene transcription. Hormone binding induces conformational changes, triggering the release of co-repressors and inducing the recruitment of coactivators that stimulate transcription. Thus, these receptors are capable of mediating dramatic changes in the level of gene activity. Disease states can be associated with defective regulation of these events. For example, in promyelocytic leukemia, fusion of RARα to other nuclear proteins causes aberrant gene silencing that prevents normal cellular differentiation. Treatment with retinoic acid reverses this repression and allows cellular differentiation and apoptosis to occur. Most type 1 steroid receptors interact weakly with co-repressors, but ligand binding still induces interactions with an array of coactivators. X-ray crystallography shows that various SERMs induce distinct estrogen receptor conformations. The tissue-specific responses caused by these agents in breast, bone, and uterus appear to reflect distinct interactions with coactivators. The receptor-coactivator complex stimulates gene transcription by several pathways, including (1) recruitment of enzymes (histone acetyl transferases) that modify chromatin structure, (2) interactions with additional transcription factors on the target gene, and (3) direct interactions with components of the general transcription apparatus to enhance the rate of RNA polymerase II–mediated transcription. Studies of nuclear receptor- mediated transcription show that these are dynamic events that involve relatively rapid (e.g., 30–60 min) cycling of transcription com plexes on any specific target gene. Nuclear receptor mutations are an important cause of endocrine disease. Androgen receptor mutations cause androgen insensitivity syndrome (AIS) (Chap. 383). Because the androgen receptor is located on the X-chromosome, mutations are more commonly manifest than with other nuclear receptor disorders. Affected individuals with AIS are XY phenotypic females with retained tes tes and male-range testosterone levels. Tissue insensitivity to androgens varies based on the severity of the mutation. Müllerian structures are absent because Sertoli cells of the testis produce AMH during development. Female carriers of androgen receptor mutations are phenotypically normal. Recessive mutations of the estrogen, glucocorticoid, and vitamin D receptors are rare. Thyroid hormone receptor β (TRβ) mutations have an unusual pathophysiology. They are autosomal dominant and function via a “dom inant negative” mechanism to cause resistance to thyroid hormone (RTH) (Chap. 375). The mutations occur in selected regions of the TRβ hormone-binding domain and preserve the abil ity of the mutant receptor to heterodimerize with RXR and bind to DNA regulatory sites. The mutant receptors function as antagonists of receptors from the normal copy of the TRβ CHAPTER 370 Mechanisms of Hormone Action Orphan Receptors SF-1, DAX-1, HNF4α Ligands Gene Expression DNA response elements Ligand induces coactivator binding Ligand dissociates corepressors and induces coactivator binding Activated + Silenced Basal Constitutive activator or repressor binding Activated Activated– + + Hormone Hormone Receptor FIGURE 370-3 Nuclear receptor signaling. AR, androgen receptor; DAX, dosage-sensitive sex-reversal, adrenal hypoplasia congenita, X-chromosome; ER, estrogen receptor; GR, glucocorticoid receptor; HNF4α, hepatic nuclear factor 4α; PPAR, peroxisome proliferator activated receptor; PR, progesterone receptor; RAR, retinoic acid receptor; SF-1, steroidogenic factor-1; TR, thyroid hormone receptor; VDR, vitamin D receptor. gene. Affected patients have high T4 and T3 and inappropriately elevated (unsuppressed) TSH, reflecting impaired feedback regulation of the hypothalamic-pituitary-thyroid axis. Organ sys tems are variably resistant to thyroid hormones based upon the relative expression of TRβ and ■REPRODUCTION 2658 TRα proteins. Mutations in the genes encoding TRα and PPARγ can also cause disease by functioning in an analogous dominant negative manner. FUNCTIONS OF HORMONES PART 12 Endocrinology and Metabolism The functions of individual hormones are described in detail in sub sequent chapters. Nevertheless, it is useful to illustrate how most biologic responses require integration of several different hormone pathways. The physiologic functions of hormones can be divided into three general areas: (1) growth and differentiation, (2) maintenance of homeostasis, and (3) reproduction. ■GROWTH Multiple hormones and nutritional factors mediate the complex phe nomenon of growth (Chap. 371). Short stature may be caused by GH deficiency, hypothyroidism, Cushing’s syndrome, precocious puberty, malnutrition, chronic illness, or genetic abnormalities that affect the epiphyseal growth plates (e.g., FGFR3 and SHOX mutations). Many factors (GH, IGF-I, thyroid hormones) stimulate growth, whereas others (sex steroids) lead to epiphyseal closure. Understanding these hormonal interactions is important in the diagnosis and management of growth disorders. For example, delaying exposure to high levels of sex steroids may enhance the efficacy of GH treatment. ■MAINTENANCE OF HOMEOSTASIS Although virtually all hormones affect homeostasis, the most impor tant among them are the following: 1. Thyroid hormone—controls about 25% of basal metabolism in most tissues. 2. Cortisol—exerts a permissive action for many hormones in addition to its own direct effects. 3. PTH—regulates calcium and phosphorus levels. 4. Vasopressin—regulates serum osmolality by controlling renal free-water clearance. 5. Mineralocorticoids—control vascular volume and serum electrolyte (Na+, K+) concentrations. 6. Insulin—maintains euglycemia in the fed and fasted states. The defense against hypoglycemia is an impressive example of integrated hormone action (Chap. 399). In response to the fasting state and falling blood glucose, insulin secretion is suppressed, resulting in decreased glucose uptake and enhanced glycogenolysis, lipolysis, proteolysis, and gluconeogenesis to mobilize fuel sources. If hypogly cemia develops (usually from insulin administration or sulfonylureas), an orchestrated counterregulatory response occurs—glucagon and epinephrine rapidly stimulate glycogenolysis and gluconeogenesis, whereas GH and cortisol act over several hours to raise glucose levels and antagonize insulin action. Although free-water clearance is controlled primarily by vaso pressin, cortisol and thyroid hormone are also important for facilitating renal tubular responses to vasopressin (Chap. 374). PTH and vitamin D function in an interdependent manner to control calcium metabolism (Chap. 402). PTH stimulates renal synthesis of 1,25-dihydroxyvitamin D, which increases calcium absorption in the gastrointestinal tract and enhances PTH action in bone. Increased calcium, along with vitamin D, feeds back to suppress PTH, thus maintaining calcium balance. Depending on the severity of a specific stress and whether it is acute or chronic, multiple endocrine and cytokine pathways are activated to mount an appropriate physiologic response. In severe acute stress such as trauma or shock, the sympathetic nervous system is activated and catecholamines are released, leading to increased cardiac output and a primed musculoskeletal system. Catecholamines also increase mean blood pressure and stimulate glucose production. Multiple stress- induced pathways converge on the hypothalamus, stimulating several hormones, including vasopressin and corticotropin-releasing hormone (CRH). These hormones, in addition to cytokines (tumor necrosis factor α, interleukin [IL] 2, IL-6) increase ACTH and GH production. ACTH stimulates the adrenal gland, increasing cortisol, which in turn helps sustain blood pressure and dampen the inflammatory response. Increased vasopressin acts to conserve free water. The stages of reproduction include (1) sex determination during fetal development (Chap. 383); (2) sexual maturation during puberty (Chaps. 384 and 385); (3) conception, pregnancy, lactation, and child rearing (Chap. 385); and (4) cessation of reproductive capability at meno pause (Chap. 388). Each of these stages involves an orchestrated interplay of multiple hormones, a phenomenon well illustrated by the dynamic hormonal changes that occur during each 28-day menstrual cycle. In the early follicular phase, pulsatile secretion of LH and FSH stimulates the progressive maturation of the ovarian follicle. This results in grad ually increasing estrogen and progesterone levels, leading to enhanced pituitary sensitivity to GnRH, which, when combined with accelerated GnRH secretion, triggers the LH surge and rupture of the mature follicle. Inhibin, a protein produced by the granulosa cells, enhances follicular growth and feeds back to the pituitary to selectively suppress FSH with out affecting LH. Growth factors such as EGF and IGF-I modulate follic ular responsiveness to gonadotropins. Vascular endothelial growth factor and prostaglandins play a role in follicle vascularization and rupture. During pregnancy, the increased production of prolactin, in combi nation with placentally derived steroids (e.g., estrogen and progester one), prepares the breast for lactation. Estrogens induce the production of progesterone receptors, allowing for increased responsiveness to progesterone. In addition to these and other hormones involved in lac tation, the nervous system and oxytocin mediate the suckling response and milk release. HORMONAL FEEDBACK REGULATORY SYSTEMS Feedback control, both negative and positive, is a fundamental feature of endocrine systems. Each of the major hypothalamic-pituitary- hormone axes is governed by negative feedback, a process that maintains hormone levels within a relatively narrow range (Chap. 371). Exam ples of hypothalamic-pituitary negative feedback include (1) thyroid hormones on the TRH-TSH axis, (2) cortisol on the CRH-ACTH axis, (3) gonadal steroids on the GnRH-LH/FSH axis, and (4) IGF-I on the GHRH-GH axis (Fig. 370-4). These regulatory loops include both positive (e.g., TRH, TSH) and negative (e.g., T4 , T3 ) components, allow ing for exquisite control of hormone levels. As an example, a small Hypothalamus Releasing factors + Pituitary Trophic hormones + CNS Target hormone feedback inhibition Adrenal Gonads Thyroid FIGURE 370-4 Feedback regulation of endocrine axes. CNS, central nervous system. 2659 reduction of thyroid hormone triggers a rapid increase of TRH and TSH secretion, resulting in thyroid gland stimulation and increased thyroid hormone production. When thyroid hormone reaches a normal level, it feeds back to suppress TRH and TSH, and a new steady state is attained. Feedback regulation also occurs for endocrine systems that do not involve the pituitary gland, such as calcium feedback on PTH, glucose inhibition of insulin secretion, and leptin feedback on the hypothalamus. An understanding of feedback regulation provides important insights into endocrine testing paradigms (see below). Positive feedback control also occurs but is not well understood. The primary example is estrogen-mediated stimulation of the midcycle LH surge. Although chronic low levels of estrogen are inhibitory, gradu ally rising estrogen levels stimulate LH secretion. This effect, which is illustrative of an endocrine rhythm (see below), involves activation of the hypothalamic GnRH pulse generator. In addition, estrogen-primed gonadotropes are extraordinarily sensitive to GnRH, leading to ampli fication of LH release. ■PARACRINE AND AUTOCRINE CONTROL The previously mentioned examples of feedback control involve clas sic endocrine pathways in which hormones are released by one gland and act on a distant target gland. However, local regulatory systems, often involving growth factors, are increasingly recognized. Paracrine regulation refers to factors released by one cell that act on an adjacent cell in the same tissue. For example, somatostatin secretion by pancre atic islet δ cells inhibits insulin secretion from nearby β cells. Autocrine regulation describes the action of a factor on the same cell from which it is produced. IGF-I acts on many cells that produce it, including chondrocytes, breast epithelium, and gonadal cells. Unlike endocrine actions, paracrine and autocrine control are difficult to document because local growth factor concentrations cannot be measured readily. Anatomic relationships of glandular systems also greatly influence hormonal exposure: the physical organization of islet cells enhances their intercellular communication; the portal vasculature of the hypo thalamic-pituitary system exposes the pituitary to high concentrations of hypothalamic releasing factors; testicular seminiferous tubules gain exposure to high testosterone levels produced by the interdigitated Leydig cells; the pancreas receives nutrient information and local expo sure to peptide hormones (incretins) from the gastrointestinal tract; and the liver is the proximal target of insulin action because of portal drainage from the pancreas. ■HORMONAL RHYTHMS The feedback regulatory systems described above are superimposed on hormonal rhythms that are used for adaptation to the environment. Seasonal changes, the daily occurrence of the light-dark cycle, sleep, meals, and stress are examples of the many environmental events that affect hormonal rhythms. The menstrual cycle is repeated on average every 28 days, reflecting the time required to follicular maturation and ovulation (Chap. 385). Essentially all pituitary hormone rhythms are entrained to sleep and to the circadian cycle, generating reproducible patterns that are repeated approximately every 24 h. The HPA axis, for example, exhibits characteristic peaks of ACTH and cortisol produc tion in the early morning, with a nadir during the night. Recognition of these rhythms is important for endocrine testing and treatment. Patients with Cushing’s syndrome characteristically exhibit increased midnight cortisol levels compared with normal individuals (Chap. 379). In contrast, morning cortisol levels are similar in these groups, as cortisol is normally high at this time of day in normal individuals. The HPA axis is more susceptible to suppression by glucocorticoids administered at night as they blunt the early-morning rise of ACTH. Understanding these rhythms allows glucocorticoid replacement that mimics diurnal production by administering larger doses in the morn ing than in the afternoon. Disrupted sleep rhythms can alter hormonal regulation. For example, sleep deprivation causes mild insulin resis tance, food craving, and hypertension, which are reversible, at least in the short term. Emerging evidence indicates that circadian clock pathways not only regulate sleep-wake cycles but also play important roles in virtually every cell type. For example, tissue-specific deletion of clock genes alters rhythms and levels of gene expression, as well as metabolic responses in liver, adipose, and other tissues. Other endocrine rhythms occur on a more rapid time scale. Many peptide hormones are secreted in discrete bursts every few hours. LH and FSH secretion are exquisitely sensitive to GnRH pulse frequency. Intermittent pulses of GnRH are required to maintain pituitary sensitiv ity, whereas continuous exposure to GnRH causes pituitary gonadotrope desensitization. This feature of the hypothalamic-pituitary-gonadotrope axis forms the basis for using long-acting GnRH agonists to treat cen tral precocious puberty or to decrease testosterone levels in the man agement of prostate cancer. It is important to be aware of the pulsatile nature of hormone secretion and the rhythmic patterns of hormone production in relating serum hormone measurements to normal val ues. For some hormones, integrated markers have been developed to circumvent hormonal fluctuations. Examples include 24-h urine collec tions for cortisol, IGF-I as a biologic marker of GH action, and HbA1c as an index of long-term (weeks to months) blood glucose control. Often, one must interpret endocrine data only in the context of other hormones. For example, PTH levels typically are assessed in combina tion with serum calcium concentrations. A high serum calcium level in association with elevated PTH is suggestive of hyperparathyroidism, whereas a suppressed PTH in this situation is more likely to be caused by hypercalcemia of malignancy or other causes of hypercalcemia. Similarly, TSH should be elevated when T4 and T3 concentrations are low, reflecting reduced feedback inhibition. When this is not the case, it is important to consider secondary hypothyroidism, which is caused by a defect at the level of the pituitary.


Navigasi Sesi 2 dari 3 · Blok Endokrin

Alur Sesi: 01 Pretest → 02 MATERI (AKTIF) → 03 POSTTEST

Broty: "Materi selesai dibaca. Lanjutkan ke posttest untuk mengevaluasi pemahamanmu pada sesi ini."

Built with LogoFlowershow